{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma+With+Sarcomatoid+Features",
    "query": {
      "condition": "Renal Cell Carcinoma With Sarcomatoid Features"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Cell+Carcinoma+With+Sarcomatoid+Features&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T19:31:22.102Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06447103",
      "title": "An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage II Renal Cell Cancer",
        "Stage III Renal Cell Cancer",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Zirconium Zr 89 Girentuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2024-08-06",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06447103"
    },
    {
      "nct_id": "NCT01767636",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma of the Collecting Ducts of Bellini",
        "Chromophobe Renal Cell Carcinoma",
        "Kidney Medullary Carcinoma",
        "Kidney Oncocytoma",
        "Metastatic Renal Cell Cancer",
        "Papillary Renal Cell Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2013-05-16",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767636"
    },
    {
      "nct_id": "NCT03483883",
      "title": "Avelumab/Gemcitabine in Sarcomatoid RCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic sRCC"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2018-03-19",
      "completion_date": "2021-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-08-26",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03483883"
    },
    {
      "nct_id": "NCT07128680",
      "title": "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Advanced Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIETARY_SUPPLEMENT",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2026-03-23",
      "completion_date": "2028-08-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Irvine, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07128680"
    },
    {
      "nct_id": "NCT03793166",
      "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Metastatic Malignant Neoplasm in the Lymph Nodes",
        "Metastatic Malignant Neoplasm in the Soft Tissue",
        "Metastatic Malignant Neoplasm in the Viscera",
        "Rhabdoid Tumor of the Kidney",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1175,
      "start_date": "2019-06-07",
      "completion_date": "2028-01-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 860,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793166"
    },
    {
      "nct_id": "NCT03055013",
      "title": "Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage II Renal Cell Cancer AJCC v7",
        "Stage III Renal Cell Cancer AJCC v7",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nephrectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 819,
      "start_date": "2017-04-28",
      "completion_date": "2031-06-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 396,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055013"
    },
    {
      "nct_id": "NCT01164228",
      "title": "Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2010-09-17",
      "completion_date": "2021-11-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 99,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Stanford, California + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164228"
    },
    {
      "nct_id": "NCT01664182",
      "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Advanced Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        },
        {
          "name": "Trebananib",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2012-08-01",
      "completion_date": "2020-12-07",
      "has_results": true,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01664182"
    },
    {
      "nct_id": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "MSI-H/dMMR Tumors",
        "Cutaneous Squamous Cell Carcinoma",
        "Urothelial Carcinoma, HCC",
        "Cervical Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Mesothelioma",
        "PD-L1 Amplified Tumor (9p24.1)",
        "Nasopharyngeal Carcinoma",
        "Cyclin-dependent Kinase 12 Mutated Tumors",
        "Basal Cell Carcinoma (Unresectable or Metastatic)",
        "Sarcomatoid Renal Cell Carcinoma",
        "Clear Cell Ovarian or Endometrial Carcinoma",
        "Anal Carcinoma",
        "Squamous Cell Penile Carcinoma",
        "DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)"
      ],
      "interventions": [
        {
          "name": "INCB099318",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2021-03-26",
      "completion_date": "2024-08-16",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 3,
      "location_summary": "Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04272034"
    },
    {
      "nct_id": "NCT07218692",
      "title": "RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Advanced Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Sturlimogene Erparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2026-08-11",
      "completion_date": "2027-08-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-06-10T19:31:22.102Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Irvine, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218692"
    }
  ]
}